StreetInsider.com News Articles

Form 8-K Lunai Bioworks Inc. For: Jun 17

Wed, 17 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260617/26660448.html

Form 8-K Lunai Bioworks Inc. For: Jun 17

Wed, 17 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260617/26660448.html

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

Lunai Bioworks (NASDAQ: LNAI) disclosed several business developments in a shareholder letter from CEO David Weinstein, including a defense contract, academic partnerships, and litigation over alleged market manipulation.

In April 2026, the Sacramento-based biotechnology company secured a multi-year defense collaboration through BioSymetrics to deploy its AI-enabled Augusta platform for chemical threat assessment, which it describes as a revenue-generating commercial engagement with the U.S. government.

The company also announced the formation of the Pathfinder Consortium, a group of institutional partners including Harvard University, Brigham and Women's Hospital, the University of Utah, Purdue University, and the University of Colorado.

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

Lunai Bioworks reports defense contract, lawsuit over short selling

Wed, 17 Jun 2026 09:15:23 -0400

In the area of precision neurology,

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Wed, 17 Jun 2026 09:15:00 -0400

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ --

Fellow Shareholders,

Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence, and national security and biology. I would like to update you on developments that have substantially strengthened our position and created multiple pathways for shareholder value creation.

A RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORM

In April 2026, we secured our first

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Wed, 17 Jun 2026 09:15:00 -0400

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ --

Fellow Shareholders,

A RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORM

In April 2026, we secured our first

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Wed, 17 Jun 2026 09:15:00 -0400

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ --

Fellow Shareholders,

A RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORM

In April 2026, we secured our first

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Wed, 17 Jun 2026 09:15:00 -0400

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ --

Fellow Shareholders,

A RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORM

In April 2026, we secured our first

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Wed, 17 Jun 2026 09:15:00 -0400

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ --

Fellow Shareholders,

A RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORM

In April 2026, we secured our first

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Wed, 17 Jun 2026 09:15:00 -0400

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ --

Fellow Shareholders,

A RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORM

In April 2026, we secured our first

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Wed, 17 Jun 2026 09:15:00 -0400

SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ --

Fellow Shareholders,

A RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORM

In April 2026, we secured our first